SCHEMBL2747760

SCHEMBL2747760

CC(C)(C)OC(=O)N1CCC(n2cc(-c3cnc(N)c(-c4cc5ccc(F)c(Cl)c5cn4)c3)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.48
MAP4K3 Q8IVH8 4/20 0.45
FGFR3 P22607 2/20 0.45
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45
TNK2 Q07912 2/20 0.44
ALK Q9UM73 2/20 0.43
NUDT1 P36639 1/20 0.43
BMPR1B O00238 1/20 0.43
PLK4 O00444 1/20 0.43
RIOK3 O14730 1/20 0.43
IKBKB O14920 1/20 0.43
CASK O14936 1/20 0.43
AURKA O14965 1/20 0.43
DCLK1 O15075 1/20 0.43
MUSK O15146 1/20 0.43
EPHB6 O15197 1/20 0.43
INPPL1 O15357 1/20 0.43
MLNR O43193 1/20 0.43
MAP3K13 O43283 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748281 0.90 MET (0.46) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2748659 0.89 MET (0.49) METMAP4K3FGFR3FGFR1FGFR2
SCHEMBL2748748 0.88 MET (0.51) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2747255 0.88 MET (0.48) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2749738 0.88 MET (0.49) METTNK2
SCHEMBL2749402 0.87 MET (0.51) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2749080 0.87 MET (0.49) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2749351 0.86 MET (0.47) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2749259 0.86 MET (0.54) METFGFR3FGFR1FGFR2TNK2
SCHEMBL2748649 0.85 MET (0.50) METTNK2MAP3K7FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MET 38/4885MAP4K3 114/4885FGFR3 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.